BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35200551)

  • 1. Gadoxetic Acid-Based MRI for Decision-Making in Hepatocellular Carcinoma Employing Perfusion Criteria Only-A Post Hoc Analysis from the SORAMIC Trial Diagnostic Cohort.
    Seidensticker M; Steffen IG; Bargellini I; Berg T; Benito A; Gebauer B; Iezzi R; Loewe C; Karçaaltincaba M; Pech M; Sengel C; van Delden O; Vandecaveye V; Zech CJ; Ricke J
    Curr Oncol; 2022 Jan; 29(2):565-577. PubMed ID: 35200551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma.
    Ricke J; Steffen IG; Bargellini I; Berg T; Bilbao Jaureguizar JI; Gebauer B; Iezzi R; Loewe C; Karçaaltincaba M; Pech M; Sengel C; van Delden O; Vandecaveye V; Zech CJ; Seidensticker M
    JHEP Rep; 2020 Dec; 2(6):100173. PubMed ID: 33103093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performing Gadoxetic Acid-Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Suh CH; Kim KW; Park SH; Kim SY; Woo DC; Shin S; Pyo J; Shinagare AB; Ramaiya NH; Lim YS
    AJR Am J Roentgenol; 2018 Feb; 210(2):W63-W69. PubMed ID: 29091004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
    Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
    Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiparametric imaging for detection and characterization of hepatocellular carcinoma using gadoxetic acid-enhanced MRI and perfusion-CT: which parameters work best?
    Kurucay M; Kloth C; Kaufmann S; Nikolaou K; Bösmüller H; Horger M; Thaiss WM
    Cancer Imaging; 2017 Jun; 17(1):18. PubMed ID: 28659180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging.
    Zech CJ; Ba-Ssalamah A; Berg T; Chandarana H; Chau GY; Grazioli L; Kim MJ; Lee JM; Merkle EM; Murakami T; Ricke J; B Sirlin C; Song B; Taouli B; Yoshimitsu K; Koh DM
    Eur Radiol; 2020 Jan; 30(1):370-382. PubMed ID: 31385048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Gadoxetic Acid-enhanced Liver MRI and Mortality in More than 30 000 Patients with Hepatocellular Carcinoma: A Nationwide Analysis.
    Kang TW; Kong SY; Kang D; Kang MW; Kim YK; Kim SH; Sinn DH; Kim YA; Choi KS; Lee ES; Woo SM; Back JH; Guallar E; Cho J
    Radiology; 2020 Apr; 295(1):114-124. PubMed ID: 32013789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.
    Semaan S; Vietti Violi N; Lewis S; Chatterji M; Song C; Besa C; Babb JS; Fiel MI; Schwartz M; Thung S; Sirlin CB; Taouli B
    Eur Radiol; 2020 Feb; 30(2):1020-1030. PubMed ID: 31673837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI.
    Kim YN; Song JS; Moon WS; Hwang HP; Kim YK
    Acta Radiol; 2018 Jun; 59(6):639-648. PubMed ID: 28825310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies.
    Li J; Wang J; Lei L; Yuan G; He S
    Eur Radiol; 2019 Dec; 29(12):6519-6528. PubMed ID: 31250172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
    Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
    Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging?
    Kim YK; Kim CS; Han YM; Park G
    Invest Radiol; 2010 Nov; 45(11):740-6. PubMed ID: 20644488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of hepatocellular carcinoma in a population at risk: iodine-enhanced multidetector CT and/or gadoxetic acid-enhanced 3.0 T MRI.
    Qiong L; Jie Z; Zhong Z; Wen S; Jun Z; Liping L; Jinkui C
    BMJ Open; 2022 Feb; 12(2):e058461. PubMed ID: 35177466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival.
    Kim HD; Lim YS; Han S; An J; Kim GA; Kim SY; Lee SJ; Won HJ; Byun JH
    Gastroenterology; 2015 Jun; 148(7):1371-82. PubMed ID: 25733098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI.
    Kitao A; Matsui O; Yoneda N; Kita R; Kozaka K; Kobayashi S; Gabata T
    AJR Am J Roentgenol; 2018 Aug; 211(2):347-357. PubMed ID: 29708786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI.
    Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
    AJR Am J Roentgenol; 2013 Sep; 201(3):675-83. PubMed ID: 23971463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study.
    Kim SS; Kim SH; Song KD; Choi SY; Heo NH
    J Magn Reson Imaging; 2020 Jan; 51(1):70-80. PubMed ID: 31062483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatobiliary phase images of gadoxetic acid-enhanced MRI may improve accuracy of predicting the size of hepatocellular carcinoma at pathology.
    Dong SY; Yang YT; Wang WT; Zhu S; Sun W; Zeng MS; Rao SX
    Acta Radiol; 2022 Jun; 63(6):734-742. PubMed ID: 33969700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The usefulness of gadoxetic acid-enhanced dynamic magnetic resonance imaging in hepatocellular carcinoma: toward improved staging.
    Choi SH; Byun JH; Kwon HJ; Ha HI; Lee SJ; Kim SY; Won HJ; Kim PN
    Ann Surg Oncol; 2015 Mar; 22(3):819-25. PubMed ID: 25201507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.